Synchronous Adenocarcinoma and Gastrointestinal Stromal Tumor in the Stomach

In recent years, the synchronous occurrence of tumors of different histotypes arising in the same organ has been reported more frequently in the literature. In the stomach, adenocarcinoma has been described with coexisting primary rhabdomyosarcoma, carcinoid, and low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. The simultaneous development of adenocarcinoma and gastric mesenchymal tumor has been documented rarely. We report one such case. A 65-year-old male was diagnosed with a proximal gastric adenocarcinoma and underwent subtotal gastrectomy. Subsequent histopathological examination revealed the presence of another tumor at the gastric antrum. This was a gastrointestinal stromal tumor of low risk category (GIST). The literature has only a few previous reports of this very rare association. It is not known whether this synchronicity is incidental or there is a causative factor inducing the development of tumors of different histotypes in the same organ. Pathologists, oncologists and surgeons should be aware of this interesting condition.     

Neoadjuvant Imatinib in Gastrointestinal Stromal Tumor of the Rectum: Report of a Case

Gastrointestinal stromal tumors are rare tumors of the gastrointestinal tract. Gastrointestinal stromal tumors involving the rectum are uncommon. We describe a case of a 43-year-old female with a gastrointestinal stromal tumor of the rectum who declined abdominoperineal resection. Neoadjuvant treatment with imatinib decreased her tumor size, permitting sphincter-sparing transanal excision. She had no evidence of disease for 24 months postoperatively until she recurred with lung metastases. Microdissection genotyping of the recurrent lesion revealed a deletion in exon 11. Further mutational analysis showed that her metastatic lesion was concordant with her primary rectal lesion, suggesting that systemic micrometastasis was previously present at initial diagnosis. Deletion in exon 11 predicts for response with imatinib treatment and is associated with a longer event-free and overall survival. Current studies are underway that may help us optimize the treatment for patients with gastrointestinl stromal tumors.Reprints are not available.     

伴反复消化道出血的小肠间质瘤1例

病例：患者男,48岁,因“间断排黑便8年,加重2d”于2010年10月19日收治入院。患者8年来无明显诱因下间断排成形黑便,时间间隔为1个月～半年不等,每次发作均为排1～5次不等的柏油样便,无恶心、呕吐,无腹痛、腹泻,     

胃血管球瘤1例

病例：患者男,34岁,因＂上腹部饱胀2年＂于2010年4月8日收治入院。患者2年前无明显诱因下出现上腹部饱胀,症状反复发作,进食后明显,以剑突下为著。无恶心、呕吐、黑便、纳差、消瘦。2年来患者多次就诊于当地医院,予抑酸、护胃等药物治疗（具体药物不详）,服药后症状可缓解。此次患者于入院前1 d门诊行胃镜检查示胃窦肿块,活检组织病理学检查示慢性轻中度非萎缩性胃炎,胃窦部隆起性病变,遂以＂胃间质瘤或异位胰腺可能＂入院行进一步诊治。     

Successful Treatment of Idiopathic Hypereosinophilic Syndrome with Imatinib Mesylate: A Case Report

Patients with idiopathic hypereosinophilic syndrome (HES) show persistent hypereosinophilia of unknown etiology that is associated with end-organ damage. Different treatments, including the use of corticosteroids and cytotoxics, have been investigated for HES with modest success. We describe a patient with HES who had significant end-organ damage from hypereosinophilia and remained refractory to conventional therapy. Therapy with imatinib mesylate, a selective tyrosine kinase inhibitor that is highly effective in treating patients with BCR-ABL-positive chronic myeloid leukemia, was tried with the patient. The result was impressive, with hematologic remission achieved after 12 days of administration. Our finding concurs with recent reports that imatinib mesylate may be a promising agent in the treatment of some cases of HES.     

First Case Report of a Sporadic Adrenocortical Carcinoma With Gastric Metastasis and a Synchronous Gastrointestinal Stromal Tumor of the Stomach

Adrenocortical carcinoma is a rare tumor with high aggresivity that can associate systemic metastases.A 71-year-old man was hospitalized for gastric cancer. The abdominal computed tomography also revealed a tumor above the right kidney. Total gastrectomy and right adrenalectomy were performed. The encapsulated tumor of the adrenal gland weighed 560 grams and presented diffuse tumor architecture under microscope, with capsular, sinusoidal, and vascular invasion. The large tumor cells had a polygonal shape, with slight basophilic, eosinophilic, or vacuolated cytoplasm, pleomorphic nuclei, and a high mitotic rate. In the stomach, the protruded tumor was covered by normal mucosa; under microscope, the tumor cells were observed only in the submucosal layer. In primary adrenal tumor and gastric metastasis the tumor cells were marked by vimentin, inhibin, synaptophysin, neuron-specific enolase, and calretinin. Based on these criteria, the diagnosis of adrenocortical carcinoma (ACC) with gastric metastasis and no lymph node metastases was established. A synchronous 10 × 10-mm-sized gastrointestinal stromal tumor (GIST) of the stomach, without mitoses, was also identified.So far, as we know, this is the 15th case of ever reported synchronous/metachronous sporadic ACCs; the ACC-related gastric metastases either synchronous ACC and GIST, has not been reported in the literature previously.     

胃肠道间质瘤的辅助治疗和新辅助治疗进展

胃肠道间质瘤(GIST)是胃肠道最常见的间叶源性肿瘤,由于酪氨酸激酶抑制剂甲磺酸伊马替尼的成功应用,该病已成为实体瘤分子靶向治疗的经典模型。目前,GIST的治疗已由原先简单的手术切除发展为针对不同病情采取包括手术、辅助治疗和新辅助治疗在内的个体化治疗策略。本文对近年来GIST的辅助治疗和新辅助治疗进展作一综述。     

胃肠道间质瘤发生的分子机制以及伊马替尼治疗研究进展

胃肠道间质瘤（GISTs）是胃肠道最常见的间叶肿瘤,其发生主要与Kit基因和血小板衍生生长因子受体（PDGFR）α基因突变有关。伊马替尼对GISTs有显著疗效,但也存在耐药问题。GISTs对伊马替尼的耐药分为原发性和继发性,原发性耐药与Kit外显子9和PDGFRα外显子18突变有关,继发性耐药与Kit基因继发性突变有关。本文就GISTs发生的分子机制以及伊马替尼治疗的进展作一概述。     

胃Dieulafoy病合并胃恶性间质瘤1例

<正> 病例:患者男,53岁,因"解柏油样便2 d"拟诊为"上消化道出血"于2010年1月8日入院。患者于1月7日中午无明显诱因下解柏油样便,量约250 g,至晚上患者出现头晕、乏力。次日下午患者再次解柏油样便,量约300 g,伴头晕、乏力加重,遂收入我科。病程中患者无腹痛、呕血、发热、晕厥,小便正常,近期无明显消瘦。患者既往无消化性溃疡史,否认肝炎、肺结核等传染病史,否认外伤手术史,否认输血史。入院查体:体温36.0℃,脉搏100次/min,呼吸18     

Central Nervous System Blast Crisis in Chronic Myeloid Leukemia on Imatinib Mesylate Therapy: Report of Two Cases

Chronic myeloid leukaemia is a chronic myeloproliferative disorder characterised by a reciprocal translocation between chromosomes 9 and 22 and thereby formation of the Philadelphia chromosome. Imatinib mesylate (STI-571) is a potent and selective inhibitor of BCR-ABL tyrosine kinase and has emerged as a treatment of choice in chronic myeloid leukaemia (CML) patients in chronic phase. It has shown activity in CML patients in the chronic phase or blastic phase. However there is poor penetration of the central nervous system (CNS) by the drug or its active metabolites. Therefore the CNS acts as a sanctuary site for malignant cells for CML patients treated with Imatinib. We report cases of two CML patients on Imatinib therapy, who were in haematological remission but developed CNS disease.     

Granular Cell Tumor of the Stomach: A Case Report and Review of the Literature

A case of granular cell tumor of the stomach in a 39-yr-old black female with peptic ulcer symptoms is presented. This lesion, a soft tissue tumor of disputed origin, has been reported in the stomach only 17 times before. In each case, the tumor was benign. Most of the patients were black, middle aged, and manifested symptoms of peptic ulcer disease. For this reason, we suggest that granular cell tumor be given serious consideration in the differential diagnosis should an upper gastrointestinal contrast study reveal a submucosal, benign mass lesion in a patient with these characteristics.     

原发性十二指肠球部溃疡型腺癌1例并文献复习

<正> 病例:患者男,74岁,因"反复黑便半年,再发5 d"于2009年1月2日入院。患者半年前无明显诱因下解柏油样稀便共3～4次,大便潜血试验阳性,伴头晕、乏力、心悸,无发热,无腹痛。至本院行胃镜检查示十二指肠球部后壁溃疡,大小约1.2 cm×1.5 cm,胃窦部活检示幽门螺杆菌(H.pylori)(+)。予泮托拉唑40 mg bid对症治疗2周,未予以H.pylori根除治疗(具体原因不详),症状完全缓解。出院后继续予泮托拉唑40 mg qd维持治疗8周。2个月前,患者欲了解溃疡愈合情况,遂于本院复查胃镜示球部溃疡未愈合,大小与第一次胃镜所见相同,胃窦部活检示H.pylori(+)。予泮托拉